{'fraction_non_alphanumeric': 0.051070840197693576, 'fraction_numerical': 0.03789126853377265, 'mean_word_length': 4.148305084745763, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
UPDATED ANALYSIS OF GENETIC SEQUENCING OF NORTH AMERICAN ATLL

response (40.6% vs 16.1% at 5 years after HSCT, P = 0.046). Among the 24 patients with primary induction failure at allo-HSCT, 15 achieved CR after allo-HSCT. The prognosis of these 15 patients was almost equivalent to that of those who received allo-HSCT in CR or PR, as shown in the Figure (P = 0.95). Regarding the stem cell source, the probability of OS was significantly higher for patients who received stem cells from CB than for those who received them from PB or BM (P = 0.04). The time from diagnosis to allo-HSCT was not different based on the stem cell sources (median CB 3.3 months, PB 3.7 months, and BM 4.1 months; P = 0.31). Patients who developed acute GVHD grade 1/2 had a significantly better prognosis than those with grade 3/4 or without GVHD (P < 0.001). At last follow-up, 42 patients (71%) had died. The most common cause of death was primary disease (62%). Conclusion: Although patients with ANKL have a poor prognosis, alloHSCT can induce stable remission even for patients with primary induction failure at HSCT. CB is a good alternative stem cell source, which enables timely allo-HSCT for this rapidly progressive disease.